Prostate cancer screening: an update
Tawadros, T.; Doerfler, A.; Treuthardt, C.; Praz, V.; Levi, F.; Zouhair, A.; Berthold, D.; Bauer, J.; Iselin, C.; Jichlinski, P.
Revue Medicale Suisse 5(228): 2438-2441
2009
ISSN/ISBN: 1660-9379 PMID: 20088117 Document Number: 14406
Prostate cancer screening using PSA is controversial because of a low specificity and detection of non clinically relevant cancer. Two important studies have been published recently. One of two studies suggests a 20% lowering in specific prostate cancer mortality due to PSA screening. This benefit is relevant but implies at a high risk of overtreatment and treatment-related complications. Currently PSA screening is only proposed as an individual screening for informed patients.
Document emailed within 1 workday
